beta
Trial Radar AI
One study matched filter criteria
Card View
Back to Search

Tirzepatide in PWS, HO and GNSO Phase 4 36

Recruiting
Clinical Trial NCT06901245 is designed to study Treatment for Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy. It is a Phase 4 interventional study that is recruiting, having started on May 1, 2025, with plans to enroll 36 participants. Led by Grace Kim, it is expected to complete by December 1, 2026. The latest data from ClinicalTrials.gov was last updated on September 16, 2025.
Brief Summary
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Detailed Description

This study is for the following individuals:

  • Age 18-26.
  • Have Prader-Willi Syndrome, Hypothalamic Obesity, or Obesity unrelated to a genetic syndrome or medical condition.
  • Have a BMI in the obesity range

If you/your child decide to take part in the research study, you/your child would participate in the study for approximately 56-60 weeks. During this time the following can be expected:

  • Receive tirzepatide ...
Show More
Official Title

The Effects of Tirzepatide in Young Adults With Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity

Conditions
Prader-Willi SyndromeHypothalamic ObesityObesity/Therapy
Other Study IDs
  • STUDY00004995
  • I8F-NS-I001 (Other Grant/Funding Number) (Lilly USA)
NCT ID Number
NCT06901245
Start Date (Actual)
2025-05-01
Last Update Posted
2025-09-16
Completion Date (Estimated)
2026-12
Enrollment (Estimated)
36
Study Type
Interventional
PHASE
Phase 4
Status
Recruiting
Keywords
Tirzepatide
GLP1 Agonist
Obesity
Prader-Willi Syndrome
Hypothalamic Obesity
General Obesity
Primary Purpose
Treatment
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Active ComparatorPrader-Willi Syndrome
Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with genetically confirmed Prader-Willi Syndrome between 18-26 years old.
Tirzepatide
Subjects will take Tirzepatide for 48 weeks
Active ComparatorHypothalamic Obesity
Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) and hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician.
Tirzepatide
Subjects will take Tirzepatide for 48 weeks
Active ComparatorGeneral Non-Syndromic Obesity
Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) and general obesity unrelated to a genetic syndrome or underlying medical condition.
Tirzepatide
Subjects will take Tirzepatide for 48 weeks
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in weight
Weight will be measured in kilograms through anthropometric measurements. Change in percent weight from baseline to week 48 of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity will then be assessed.
48 weeks
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in BMI
Change in BMI from baseline to 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity through anthropometric measurements. BMI will be calculated using weight (kg) and height (m) which will be combined to report BMI in kg/m\^2. The percent change in this BMI value from baseline to 48 weeks will be calculated.
48 weeks
Change in fat mass
Change in fat mass (measured in kg by DXA scan) from baseline to 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity.
48 weeks
Change in appetite - CoEQ (Control of Eating Questionnaire)
Change in appetite during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity using an appetite questionnaire (CoEQ - Control of Eating Questionnaire). CoEQ is a 21-item scale to assess the severity and type of food cravings an individual experiences using a visual analog scale. Higher scores indicate higher severity of hyperphagia.
48 weeks
Change in appetite - Physician Rated Hyperphagia Severity Scale
Change in appetite during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity assed with a physician rated hyperphagia severity scale. This is a 5 point scale (0 to 5) to rate clinical imppression of hyperphagia severity. Higher scores mean more severity.
48 weeks
Change in metabolic markers - fasting lipids
Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: fasting lipids via lipid profile assay via blood sample
48 weeks
Change in metabolic markers - fasting plasma glucose
Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: fasting plasma glucose, via chemistry panel via blood sample
48 weeks
Change in metabolic markers- fasting insulin
Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: fasting insulin via insulin assay via blood sample
48 weeks
Change in metabolic markers - hemoglobin A1C
Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: hemoglobin A1C via hemoglobin A1C assay via blood sample
48 weeks
Change in metabolic markers- Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Change in metabolic markers during 48 weeks of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity including: Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). This is product measuring insulin resistance calculated using fasting insulin and fasting glucose values. Higher numbers indicate more insulins resistance.
48 weeks
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition
  • In a stable care setting at least 6 months prior to enrollment
  • Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan.
  • Ability to take weekly subcutaneous tirzepatide
  • Consistent caregiver if they are not independent
  • Stable diet and exercise regimen for at least 6 months prior to enrollment
  • Able to use contraceptive methods if able to conceive offspring in order to prevent unintentional pregnancy during the study

  • Current or recent (within 3 months of start of study drug initiation) use of weight loss medications
  • Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance
  • Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening
  • Any medications that may affect the study endpoints
  • Significant weight change (>3% weight gain or loss) in the last 2 months prior to enrollment
  • Change in dose of chronic endocrine medications (testosterone, estrogen, levothyroxine, or growth hormone medications) >10%/kg/day for at least 3 months prior to study
  • Current pregnancy or desire to become pregnant within study period, current lactation
  • History of recurrent pancreatitis, CKD, gastroparesis
  • Chronic/acute heart, kidney, or liver disease
  • Personal or family history of medullary thyroid carcinoma or MEN syndrome type 2
  • Uncontrolled diabetes (A1C >8.5%)
  • DVT
  • Cancer within the previous 5 years
  • Current participation in an interventional clinical study
  • Previous or planned surgical treatment for obesity
  • Individuals with current substance abuse equivalnt to moderate or severe based on DSM 5 criteria (Hasin DS, 2013)
  • Any suicidal ideation in the past year
  • Unable to perform any of the procedures for the study
  • Have a body weight, height, and/or width that that prohibits the ability to obtain accurate measurements according to the DXA manufacturer's specification
  • Any condition that would prevent successful participation in the study.
Grace Kim logoGrace Kim
Study Responsible Party
Grace Kim, Sponsor-Investigator, Principal Investigator, Seattle Children's Hospital
No contact data.
3 Study Locations in 1 Countries

Minnesota

Children's Minnesota, Saint Paul, Minnesota, 55102, United States
Diabetes/Endocrinology Research Team, Contact, 651-220-5730, [email protected]
Jennifer Abuzzahab, MD, Principal Investigator
Recruiting

Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee, 37203, United States
Martha Upchurch, Contact, 6158754274, [email protected]
Ashley Shoemaker, MD, Principal Investigator
Recruiting

Washington

Seattle Children's Hospital, Seattle, Washington, 98105, United States
Endocrine Research Team, Contact, 206-987-2540, [email protected]
Grace Kim, MD, Principal Investigator
Parisa Salehi, MD, Sub-Investigator
Melinda Pierce, MD, Sub-Investigator
Recruiting